Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Mutations in FMS-like tyrosine kinase 3 (FLT3), such as internal tandem duplications (ITDs), can be found in up to 23% of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Current treatment options for FLT3(ITD)-positive AMLs include genotoxic therapy and FLT3 inhibitors (FLT3i...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Maifrede, Silvia, Nieborowska-Skorska, Margaret, Sullivan-Reed, Katherine, Dasgupta, Yashodhara, Podszywalow-Bartnicka, Paulina, Le, Bac Viet, Solecka, Martyna, Lian, Zhaorui, Belyaeva, Elizaveta A., Nersesyan, Alina, Machnicki, Marcin M., Toma, Monika, Chatain, Nicolas, Rydzanicz, Malgorzata, Zhao, Huaqing, Jelinek, Jaroslav, Piwocka, Katarzyna, Sliwinski, Tomasz, Stoklosa, Tomasz, Ploski, Rafal, Fischer, Thomas, Sykes, Stephen M., Koschmieder, Steffen, Bullinger, Lars, Valent, Peter, Wasik, Mariusz A., Huang, Jian, Skorski, Tomasz
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2018
Onderwerpen:
Myeloid Neoplasia
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034642/
https://ncbi.nlm.nih.gov/pubmed/29784639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-834895
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items